ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE)

BRIEF

published on 04/30/2025 at 07:35, 10 months 24 days ago

OSE Immunotherapeutics présente une nouvelle signature d'expression génique à l'AACR 2025

Immuno-oncologie Blocage Du Point De Contrôle Immunitaire Signature D'expression Génétique Traitement Personnalisé Prédiction Du Cancer
BRIEF

published on 04/30/2025 at 07:35, 10 months 24 days ago

OSE Immunotherapeutics Presents New Gene Expression Signature at AACR 2025

Immuno-oncology Personalized Treatment Immune Checkpoint Blockade Gene Expression Signature Cancer Prediction
PRESS RELEASE

published on 04/30/2025 at 07:30, 10 months 24 days ago

Immuno-Oncology Results from Research Collaboration with Léon Bérard Cancer Center Presented at AACR Annual Meeting 2025
OSE Immunotherapeutics and Léon Bérard Cancer Center present a new gene expression signature for predicting clinical response to immune checkpoint at AACR Annual Meeting 2025

AACR Annual Meeting OSE Immunotherapeutics Gene Expression Signature Léon Bérard Cancer Center Clinical Response Prediction
BRIEF

published on 04/09/2025 at 07:35, 11 months 15 days ago

OSE Immunotherapeutics présentera des données sur le lusvertikimab au DDW 2025

Rectocolite Hémorragique OSE Immunotherapeutics Lusvertikimab DDW 2025 Extension De La Phase 2
BRIEF

published on 04/09/2025 at 07:35, 11 months 15 days ago

OSE Immunotherapeutics to Present Data on Lusvertikimab at DDW 2025

Ulcerative Colitis OSE Immunotherapeutics Lusvertikimab Phase 2 Extension DDW 2025
PRESS RELEASE

published on 04/09/2025 at 07:30, 11 months 15 days ago

OSE Immunotherapeutics présentera des données inédites de la période d’extension de Lusvertikimab à la “Digestive Disease Week” (DDW) 2025
OSE Immunotherapeutics présentera des données inédites de la période d’extension de Lusvertikimab à la Digestive Disease Week (DDW) 2025

Rectocolite Hémorragique OSE Immunotherapeutics Lusvertikimab Anticorps Monoclonal Efficacité Et Sécurité
PRESS RELEASE

published on 04/09/2025 at 07:30, 11 months 15 days ago

OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025
OSE Immunotherapeutics to present new data on Lusvertikimab's long-term benefits and safety in ulcerative colitis at DDW 2025, showcasing potential in autoimmune diseases

Ulcerative Colitis Immuno-oncology Inflammatory Diseases OSE Immunotherapeutics Lusvertikimab
BRIEF

published on 11/04/2024 at 07:35, 1 year 4 months ago

OSE Immunotherapeutics révèle des résultats prometteurs de phase 2 pour le traitement de la colite ulcéreuse

Rectocolite Hémorragique Étude De Phase 2 Résultats Cliniques Lusvertikimab OSE Immunothérapie
BRIEF

published on 11/04/2024 at 07:35, 1 year 4 months ago

OSE Immunotherapeutics Reveals Promising Phase 2 Results for Ulcerative Colitis Treatment

Ulcerative Colitis Phase 2 Study OSE Immunotherapeutics Clinical Results Lusvertikimab
PRESS RELEASE

published on 11/04/2024 at 07:30, 1 year 4 months ago

OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis
OSE Immunotherapeutics reports positive results from Phase 2 study of Lusvertikimab for Ulcerative Colitis treatment. Primary endpoint met with high clinical and endoscopic remission rates

Positive Results Phase 2 Study OSE Immunotherapeutics Lusvertikimab Ulcerative Colitis Treatment

Published on 03/24/2026 at 23:42, 4 hours 20 minutes ago

Presentation to Gold Coast Gold Conference
Published on 03/24/2026 at 23:00, 5 hours 2 minutes ago

Redwood AI Selected to Present at BIO-Europe Spring 2026, Europe's Largest Springtime Biotech Partnering Event
Published on 03/24/2026 at 18:55, 9 hours 7 minutes ago

Norse Gold Announces Closing of Private Placement Financing and Pending Reactivation on the TSX-V
Published on 03/24/2026 at 13:30, 14 hours 32 minutes ago

GGL Resources Corp. Announces Closing of Earn-In Agreement with Nelson Resources Limited on Its Gold Point High-Grade Gold-Silver Project, Nevada
Published on 03/24/2026 at 13:30, 14 hours 32 minutes ago

Innodata Announces Date of Annual Shareholder Meeting

View all ACCESSWIRE

Published on 03/24/2026 at 21:08, 6 hours 54 minutes ago

Linedata Services: Linedata annonce le transfert de son contrat de liquidité auprès de Portzamparc (Groupe BNP Paribas)
Published on 03/24/2026 at 19:49, 8 hours 13 minutes ago

EEII AG: Cancellation of the Extraordinary General Meeting of March 26, 2026
Published on 03/24/2026 at 19:41, 8 hours 20 minutes ago

ASMALLWORLD Honoured with Regional Virtuoso Award in Continental Europe for “Most Engaged Member” in Recognition of Their Exceptional Contribution
Published on 03/24/2026 at 19:05, 8 hours 57 minutes ago

WBS Power Advances 3.2 GW Energy Infrastructure for Hyperscale Data Center Campus
Published on 03/24/2026 at 18:39, 9 hours 22 minutes ago

EQS-Adhoc: FORTEC Elektronik Aktiengesellschaft: Adjustment of the earnings forecast for the financial year 2025/2026

View all EQS

Published on 03/24/2026 at 18:21, 9 hours 41 minutes ago

Résultats annuels 2025
Published on 03/24/2026 at 18:21, 9 hours 41 minutes ago

2025 Annual results
Published on 03/24/2026 at 18:00, 10 hours 2 minutes ago

i2S : Résultats annuels 2025
Published on 03/24/2026 at 17:46, 10 hours 16 minutes ago

NRJ GROUP - Avis résultats annuels 2025
Published on 03/24/2026 at 17:46, 10 hours 16 minutes ago

NRJ GROUP - Press release annual results 2025

View all LES ECHOS COMFI WIRE

News